Page 12 - U11248 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from U11248. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In U11248 Today - Breaking & Trending Today

Immunotherapy Linked to Lower Relapse Risk in MOGAD

Treatment with immunotherapy is tied to a lower risk for relapse in patients with myelin oligodendrocyte glycoprotein antibody disease (MOGAD), new research shows. ....

United States , Michael Cossoy , Philippe Bilodeau , Americas Committee For Treatment , Research In Multiple Sclerosis , University Of Manitoba , Americas Committee , Multiple Sclerosis , Massachusetts General , Multiple Sclerosis Ms , Multiple Sclerosis , Biologic Therapy , Antineoplastic Drug , Nti Cancer Agents , Monoclonal Antibody , Vision Care And Maintenance , Intravenous Immunoglobulin , Acute Disseminated Encephalom ,

HER2-Low Breast Cancer Is NOT a Separate Clinical Entity: Study

A large-scale analysis has revealed few biological and prognostic differences between HER2-low and HER2-negative breast cancer, and they should not be treated differently, say clinicians. ....

United States , Susang Komen , Giuseppe Curigliano , Frederickm Howard , Breast Cancer Research Foundation , National Cancer Database , Department Of Defense , National Institutes Of Health Cancer Institute , Us National Cancer Database , University Of Chicago , Early Drug Development For Innovative Therapies Division , European Institute Of Oncology , Department Of Medicine , Cancer Database , New Drugs , Early Drug Development , Innovative Therapies Division , European Institute , Antonio Breast Cancer Symposium , Medscape Medical News , Medscape Medical , Hispanic White , American Society , Conquer Cancer Foundation , National Institutes , National Cancer Institute ,

Long-Term Benefit From Nivolumab Plus Cabozantinib in RCC

First-line nivolumab plus cabozantinib continues to show superiority to sunitinib in the treatment of patients with advanced advanced renal cell carcinoma (RCC). ....

New York , United States , Mauricio Burotto , Benjamina Gartrell , Manuela Schmidinger , Bradford Hill Clinical Research Center , Albert Einstein College Of Medicine , Rcc Database Consortium , University Of Vienna , Genitourinary Cancers Symposium , New England Journal , All Endpoints , Medical University , Genitourinary Malignancy Program , Montefiore Einstein Cancer Center , Albert Einstein College , Malignant Kidney Neoplasm , Kidney Cancer , Renal Cell Cancer , Renal Cell Carcinoma , Ancer Kidney , Ancer Renal Cell , Antineoplastic Drug , Nti Cancer Agents , Biologic Therapy , Tyrosine Kinase Inhibitor ,

Leukemia: Preventing Chemotherapy-Induced Vascular Toxicity

Tyrosine kinase inhibitors markedly improve patients chances of survival but also cause a rise in blood pressure that must be treated quickly. ....

France General , Gabrielle Sarlon , Marseille University Hospital , European Society Of Cardiology , European Days , French Society , Cardiology Conference , European Society , Chronic Myelogenous Leukemia , Chronic Leukemia , Patient Safety , Biologic Therapy , Ipid Management , Tyrosine Kinase Inhibitor , Doppler Ultrasonography , Cardiovascular Imaging , Ardiac Imaging , V Imaging , Adverse Effects , Side Effects , Tyrosine Kinase , Peripheral Vascular Disease ,

How Medicare Could Save $1.29 Billion a Year on Urology Drugs

Medicare could save more than $1 billion each year just on urology drugs by using Mark Cuban s cost-plus drug pricing model, new findings suggest. ....

United States , Vanderbilt University , Mark Cuban , Ruchika Talwar , Urologic Oncology At Vanderbilt University Medical Center , Mark Cuban Cost Plus Drug Company , Urologic Oncology , Vanderbilt University Medical Center , Medscape Medical News , Rxpreferred Benefits , Preferred Benefit , Mark Cuban Cost Plus Drugs , Published February , Practice Management , Generic Drug , Eneric Medication , Drug Costs , Biologic Therapy , Prostate Carcinoma , Alignant Prostate Neoplasm , Prostate Cancer , Ancer Prostate , Acute Leukemia , Chronic Myelogenous Leukemia , Health Insurance , Antineoplastic Drug ,